INTRODUCTION
============

Corticotropin-releasing factor (CRF) was discovered in 1981 by Vale and colleagues at the Salk Institute ([@B125]). Its existence had been hypothesized for many years prior to the 1981 paper characterizing the amino acid sequence of the peptide. Since then, the importance of CRF family of peptides and receptors in stress has steadily emerged. Extensive investigation has demonstrated that CRF is critical in regulating the hypothalamic-pituitary-adrenal (HPA) axis and in integrating endocrine, autonomic, and behavioral responses to stressors ([@B93]).

In addition to CRF, additional members of the CRF peptide family including urocortins (Ucns) 1, 2, and 3 have been identified in mammals, including humans ([@B128]; [@B46]; [@B66]; [@B98]). Accumulating evidence suggests that the central actions of Ucn peptides may account for some stress-related effects originally attributed to CRF ([@B5]; [@B43]; [@B129]; [@B49]; [@B61]). For example, Ucn 1 appears to be involved in the later stage of the stress response and adaptation to stress, while Ucns 2 and 3 may be involved in attenuating the stress response ([@B102]).

Additionally, the Ucns have been shown to be involved in various physiological regulations including energy balance, cardiovascular function, and behavioral modulation. Ucn 1, 2, and 3 all suppress feeding ([@B111]; [@B43]; [@B34]), and deficiency in Ucn 2 improves glucose and insulin homeostasis ([@B19]). Ucn 1 and 2 decrease cardiac output and heart rate, and may be protective against ischemia ([@B64]; [@B4]; [@B43]). Behaviorally, Ucn 1 plays a critical role in anxiety-like and depressive behavior, and may be involved in the predisposition of alcohol consumption ([@B130]; [@B102]). Ucn 2 may be linked to depression but not anxiety ([@B102]). Ucn 2 appears to influence social behavior, including aggression ([@B12]), as mice deficient in Ucn 2 are less aggressive and prefer passive social interaction. Finally, Ucn 1 and CRF receptors have been found in the auditory system ([@B39]) and the peptide appears to be involved in the development and maintenance of hearing ([@B130]).

Urocortin 3 is the latest addition of the CRF family of peptides, initially identified in the brains of humans and rodents ([@B46]; [@B66]). Sequence analyses show that Ucn 3 is more closely related to Ucn 2 than Ucn 1 or CRF. Human and mouse Ucn 3 share 40% homology with human and mouse Ucn 2, but only 21 and 18%, respectively, with human and mouse Ucn 1 and 32 and 26% with CRF ([@B66]). Accumulating evidence, as discussed below, has suggested that Ucn 3 is a critical regulator in energy homeostasis.

CORTICOTROPHIN-RELEASING FACTOR RECEPTORS
=========================================

Two receptors have been identified for CRF: type 1 and type 2 CRF receptors (CRF~1~ and CRF~2~), and amino acid sequence analysis has shown that the two receptors share approximately 70% homology ([@B93]; [@B5]). Both CRF~1~ and CRF~2~ are G-protein-coupled receptors with seven transmembrane domains. These receptors signal predominantly through increased cAMP production, but additional signaling pathways including Ca^2+^, mitogen-activated protein kinase (MAPK), phospholipase C, protein kinase B, and ion channels have also been shown to couple to CRFRs ([@B52]; [@B40]; [@B11]). The two receptors differ significantly in their binding affinity for CRF peptides and anatomical distribution within the central nervous system ([@B17]; [@B127]; [@B46]; [@B66]). Biochemical studies have shown that CRF binds CRF~1~ with high affinity while showing modest affinity for CRF~2~ ([@B5]). Ucn 1 binds both CRF~1~ and CRF~2~ with equally high affinity while Ucn 2 and Ucn 3 demonstrate preferential specificity for CRF~2~. However, while Ucn 2 may bind and stimulate CRF~1~ at high, pharmacological concentrations ([@B98]), Ucn 3 is highly selective to CRF~2~ and displays minimal affinity for CRF~1~ ([@B46]; [@B66]).

A circulating protein has been identified that binds CRF. It has been suggested that the function of CRF binding protein (CRFBP) is mainly to sequester CRF to reduce its HPA axis stimulation. Levels of CRFBP are elevated in pregnancy to dampen the negative effect of stress responses on the developing fetus ([@B38]). In addition to CRFBP, a splice variant of CRF~2~ has been identified that contains only the extracellular domain of the receptor and shown to circulate, bind, and sequester CRF as well ([@B10]; [@B20]). This splice variant also binds Ucn 1 but has very low affinity for Ucn 2 and 3 ([@B20]).

Anatomical mapping studies have demonstrated that CRF~1~ and CRF~2~ have distinct distributions in the brain. CRF~1~ has a wide distribution throughout the brain with high density in the medial septal area, amygdala, and cerebellum ([@B17]; [@B127]). CRF~2~ has three major variants that differ in their N-terminal domains: CRF~2(a)~, CRF~2(b)~, and CRF~2(c)~. In murine brains, CRF~2(a)~ is predominantly expressed in the hypothalamus, lateral septum (LS), and dorsal raphe ([@B17]; [@B127]). CRF~2(b)~ is found predominantly in the periphery, including in skeletal muscle, the gastrointestinal tract, and the heart ([@B51]; [@B132]; [@B94]; [@B118]). CRF~2(c)~ is found only in the human brain ([@B56]).

The function of CRF~1~ has been closely associated with the stress response, including the release of adrenocorticotropic hormone (ACTH) from the anterior pituitary and behavioral adaptation to stressors ([@B5]). The physiological role of CRF~2~, however, is less defined. Functional studies have shown this receptor is involved in an array of homeostatic regulations, with most of its actions regulating energy balance by modulating feeding, blood glucose levels, and energy expenditure. This review will focus on recent advances in the understanding of the physiological role of CRF~2~ and Ucn 3 in the brain, particularly in the hypothalamus, in the regulation of energy balance.

CRF~2~ IN ENERGY HOMEOSTASIS
============================

Loss-of-function studies with CRF~2~ null mice and pharmacological studies with CRF~2~ agonists both suggest that endogenous CRF~2~ plays a physiological role in energy balance. Evidence from several studies that examined ingestive behavior of CRF~2~ null mice showed that endogenous CRF~2~ is required for the anorectic effect of CRF peptide and is involved in control of the meal size during active phase of eating and following acute exposure to the stress ([@B3]; [@B24]; [@B90]; [@B117]). Similarly, infusion of antisense oligonucleotides to CRF~2~ mRNA attenuates both CRF and Ucn 1-induced hypophagia and corticosterone secretion ([@B109]). Furthermore, CRF~2~ deletion protects mice from high-fat diet-induced insulin resistance and glucose intolerance ([@B2]). Taken together, it is clear that CRF~2~ is responsible for mediating the effect of CRF family peptides on the suppression of feeding and is involved in corticosterone secretion and glucose homeostasis.

In addition to feeding, CRF~2~ is involved in regulating energy expenditure. CRF~2~ knockout (KO) mice have more active metabolism and lose heat faster than wildtype (WT) mice ([@B14]), suggesting an exaggerated level of sympathetic activity. Moreover, CRF~2~ KO mice have higher brown adipose tissue (BAT) temperature and, when given a choice between room temperature and warm areas, prefer warmer areas more than WT mice ([@B14]). The KO mice also have higher oxygen consumption and carbon dioxide production and reduced respiratory exchange rate ([@B14]), indicating a preference in fatty acid oxidation over carbohydrate utilization in the KO mice. It was suggested that a lack of functional CRF~2~ leads to elevated CRF~1~ activity, which consequently increases sympathetic nervous system (SNS) activity to promote lipolysis ([@B14]). This hypothesis appears to disagree with pharmacological studies, as activation of central CRF~2~ (discussed below), in most cases, results in increased SNS activity. This apparent discrepancy may result from a number of possibilities including compensatory mechanisms due to total body KO of the receptor as compared to acute, local stimulation of the receptor in the brain. Obviously more studies are needed to further elucidate this issue.

Leptin, a hormone secreted by adipocytes, is a potent appetite suppressant ([@B124]; [@B136]). A number of studies suggest that its effect on feeding may involve the CRF receptor system. Though leptin treatment greatly decreases food intake, when co-administered with a non-selective CRF receptor antagonist, food intake remains at a nearly normal level ([@B37]), suggesting the CRF system is a downstream target of leptin in the brain. However, this notion was recently challenged by a study ([@B42]) demonstrating that CRF~2~ is not essential for the effects of leptin on energy balance, including feeding and body weight regulation. Again this discrepancy may be due to the nature of global CRF~2~ KO, which potentially results in functional compensation such as exaggerated CRF~1~ activity in these mice ([@B14]). Therefore, central or specific brain area deletions of CRF~2~ may be necessary to further evaluate the interaction of leptin and the CRF system in the brain.

UROCORTIN 3
===========

ANATOMICAL LOCATION OF Ucn 3
----------------------------

Urocortin 3 is found both in the periphery and in the brain. In the periphery, it is expressed in the digestive tract, muscle, thyroid and adrenal glands, pancreas, heart, spleen, and skin ([@B46]; [@B66]). In the brain, neurons expressing Ucn 3 are concentrated in the medial amygdala (MeA) and hypothalamus ([@B66]; [@B70]). In the hypothalamus, the major Ucn 3 cell population is near the rostral perifornical hypothalamic area (rPFA; [@B70]). Specifically, Ucn 3-positive cells are gathered around the fornix lateral to the paraventricular nucleus of the hypothalamus (PVH). This group extends rostrally and stays close to the fornix into the posterior part of the bed nucleus of the stria terminalis (pBNST) and medially into the anterior parvicellular part of the PVH (PVHap). A recent study has elucidated anatomical heterogeneity within this hypothalamic Ucn 3 cell population, as neurons of the rostral part (PVHap/pBNST) project to the ventromedial hypothalamus (VMH), and those of the caudal part, residing in the rostral perifornical hypothalamus (rPFH), projects to the LS ([@B21]). A second group of Ucn 3-positive cells is found in the median preoptic nucleus (MnPO; [@B70]). In the forebrain, prominent Ucn 3 nerve fibers and terminals are found in the VMH, LS, MeA, and BNST ([@B70]). These areas also express high levels of CRF~2~ ([@B17]; [@B127]). This overlap of Ucn 3 and CRF~2~ distribution and the high affinity of the peptide for the receptor strongly suggest that Ucn 3 is an endogenous ligand for CRF~2~ in these brain areas.

METABOLIC EFFECTS OF Ucn 3
--------------------------

All 3 Ucns bind CRF~2~ and may each be responsible for some of the receptor's energy homeostatic effects. However, Ucn 3 alone has myriad metabolic effects.

### Feeding

Central administration, KO, and overexpression studies reveal a role of Ucn 3 in the regulation of feeding. When directly infused into the lateral ventricles, Ucn 3 decreases nocturnal food and water intake in a dose dependent manner, primarily due to decreased meal frequency, and this effect was eliminated with concomitant CRF~2~ antagonist treatment ([@B34]). The anorectic effect of Ucn 3 is not due to distaste for food, as no concurrent taste aversion develops ([@B34]). Consistent with pharmacological evidence, genetic Ucn 3 deficiency appears to lead to overeating. Though Ucn 3 KO mice have similar body weights to WT animals, KO mice eat more and have increased accumulated food intake. Similar to CRF~2~ null mice, Ucn 3 KO mice exhibit elevated nocturnal feeding, when greatest spontaneous food intake naturally occurs ([@B18]). Taken together, it is clear that Ucn 3 in the brain functions as a potent anorectic agent. However, a study that used genetic overexpression of Ucn 3 challenged this notion. Under regular chow-fed condition, mice with overexpression of Ucn 3 (*Ucn3+*) have higher body mass-adjusted food intake than WT and are heavier than WT controls due to increased lean body mass ([@B48]). On the other hand, *Ucn3+* mice do not gain as much weight as WT mice when fed with a high-fat diet ([@B48]). This result seems to be in line with the notion of Ucn 3 as an anorectic agent. The discrepancy between different mouse models can be due to a number of possibilities including the ramification of Ucn 3 overexpression both in the brain as well as in the periphery.

A temporally and spatially controlled viral approach to overexpress Ucn 3 in the rPFH shows that Ucn 3 in the rPFH does not modulate food intake ([@B61]), as mice with Ucn 3 overexpression in the rPFH ingest consume similar amount of food as control mice ([@B61]). The rPFH-specific Ucn 3-overexpressing mice show a trend toward being heavier, but retain the same fat--lean mass percentages as control mice ([@B61]). As mentioned above, Ucn 3 cells in the rPFH project mainly to the LS with minimal projection to the VMH. Therefore, it is reasonable to assume that CRF~2~ in the LS will be overstimulated in this mouse model. Interestingly, a number of studies have shown that CRF~2~ in the LS is involved in suppression of food intake ([@B131]; [@B1]). Currently, it is unclear as to why overexpression of Ucn 3 in the rPFH fails to suppress feeding. The expression of CRF receptor has been shown to be subject to ligand-induced receptor down-regulation ([@B96]; [@B30]). It is conceivable that chronic elevated Ucn 3 input to the LS in Ucn 3 rPFH overexpression mice may lead to alteration in CRF~2~ expression and consequently reduced response to Ucn 3 stimulation in the LS. Thus, it is possible that acute stimulation of CRF~2~ in the LS suppresses feeding, but chronic stimulation of CRF~2~ in the LS in mice with Ucn 3 overexpression in the rPFH may lead to negative feedback to balance the effect of CRF~2~ in feeding. Clearly, more studies are needed to elucidate the effect of Ucn 3 overexpression in the regulation of food intake. In addition to Ucn 3, Ucn 1 neurons in the midbrain Edinger--Westphal nucleus have been shown to innervate the LS ([@B57]; [@B9]). Therefore, both Ucn 1 and 3 may contribute to the effect of CRF~2~ on feeding in the LS.

The mechanism of Ucn 3-induced anorexia has not been directly studied. Central administration of CRF~2~ agonists, including Ucn 3, have been shown to inhibit gastric emptying ([@B78]; [@B112]), and elevate blood glucose levels ([@B49]; [@B22]). Both reduced gut motility and hyperglycemia have been shown to induce satiation and reduce feeding ([@B100]; [@B26]; [@B133]; [@B16]). Therefore, multiple mechanisms are potentially involved in mediating the anorectic effect of Ucn 3 in the brain.

### Energy homeostasis

Similarly to CRF~2~, Ucn 3 is also involved in energy expenditure. Central administration of Ucn 3 increases motor activity ([@B87]). Similarly, transgenic Ucn 3 overexpression mice (*Ucn3+*) have an increased respiratory exchange ratio and increased motor activity in their home cages ([@B48]). Furthermore, mice with Ucn 3 overexpressed in the rPFH had an increased respiratory exchange ratio and elevated heat production ([@B61]). This is consistent with the notion that Ucn 3 is involved in SNS activity and energy homeostasis. Ucn 3 KO mice, on the other hand, do not show the same pattern; there are no differences in oxygen consumption, heat production, or activity levels ([@B18]). Therefore, KO of Ucn 3 in specific brain areas may provide better insight into the role of specific populations of Ucn 3 cells in the brain in energy expenditure.

### Glucose homeostasis

Several studies have revealed a complex role of Ucn 3 in glucose homeostasis. Though adult Ucn 3 KO mice fed a chow diet show no differences in glucose tolerance and insulin sensitivity compared to WT mice ([@B68]), Ucn 3 KOs have lower basal insulin levels and show a greater rebound in blood glucose levels after the initial hypoglycemia during an insulin tolerance test ([@B68]; [@B18]). Furthermore, under high-fat diet feeding, adult KO mice are more metabolically resilient. The Ucn 3 KO mice have lower plasma insulin and blood glucose concentrations than WT mice, remain sensitive to insulin and do not develop glucose intolerance and liver steatosis with the same frequency of WT mice ([@B68]). Moreover, aged KO mice show better glucose homeostasis than age-matched WT mice ([@B68]). Overall, Ucn 3 deficiency appears to protect the mice from metabolic disorders caused by high-fat feeding. It is noteworthy that Ucn 3 is expressed in pancreatic β cells and has been shown to play a critical role as a local regulator in insulin secretion ([@B67]). Thus, it is likely that Ucn 3 in both the brain and in the periphery, especially in the pancreas, contribute to the phenotypes observed in Ucn 3 null mice.

On the other hand, *Ucn3+* transgenic mice also appear to be protected against excessive metabolic challenge, having decreased fed and fasting blood glucose levels and increased tolerance to glucose when challenged in a glucose tolerance test ([@B48]). Fasting insulin levels in *Ucn3+* mice are also lower than that in WT mice, though an insulin tolerance test shows no differences in insulin sensitivity ([@B48]). When challenged with a high-fat diet, *Ucn3+* mice fare better than the WT littermates, maintaining normal body weight and low blood glucose levels, but display comparable insulin sensitivity to the WT control mice ([@B48]). Though *Ucn3+* mice show improved glucose homeostasis and insulin sensitivity, overexpression of Ucn 3 in the rPFH produces the opposite effect; rPFH Ucn 3-overexpressing mice show reduced insulin sensitivity and increases basal insulin levels, however they show no difference in glucose tolerance ([@B61]).

While genetic KO of Ucn 3 appears to have metabolic protective qualities, the effect of Ucn 3 overexpression is unclear. Full body overexpression of Ucn 3 seems protective, while targeted overexpression within the rPFH appears metabolically detrimental. Interestingly, *Ucn3+* mice have lower fasting blood glucose levels and higher energy intake under basal conditions ([@B48]). As stated earlier, CRF~2~ is expressed abundantly in a number of peripheral tissues including skeletal muscle ([@B92]; [@B113]; [@B132]; [@B94]; [@B62]). Stimulation of muscle CRF~2~ has been shown to promote thermogenesis ([@B110]). Moreover, muscle CRF~2~ is involved in regulating skeletal muscle mass ([@B45]) and consistent with this notion, *Ucn3+* mice have increased muscle mass ([@B48]). Thus, it is conceivable that the improved glucose homeostasis of *Ucn3+* mice is due, at least in part, to stimulation of muscle CRF~2~ by ectopic overexpression of Ucn 3 in the periphery.

### Thermoregulation

Functional studies have shown that Ucn 3 is involved in thermoregulation, potentially acting on brown fat. It was found that Ucn 3 induced a significant increase in body temperature, from 37.2 to 38.6°C (99.0 to 101.5°F), when injected into the lateral ventricles of rats ([@B122]). Temperature gradually decreased after peaking 2 h after Ucn 3 administration, but remained significantly elevated for a total of 4 h ([@B122]). Moreover, pretreating animals with CRF~2~ but not CRF~1~ antagonists completely blocked Ucn 3-induced hyperthermia, indicating that the pyrogenic action of Ucn 3 is mediated by CRF~2~ ([@B121]). Noraminophenazone, a cyclooxygenase inhibitor, simultaneously applied with Ucn 3 also prevented the temperature increase and also attenuated the increase when administered 30 min after Ucn 3 treatment ([@B122]). This indicates that the arachidonic acid cascade forming prostaglandin is a downstream target of central Ucn 3 and CRF~2~ system in thermoregulation. Currently, the brain loci that may mediate the effect of Ucn 3 in body temperature remain elusive. The MnPO is known to be a center for thermoregulation and expresses high concentrations of the prostaglandin receptor EP3 ([@B81]). It has been shown that prostaglandins play an important role in the MnPO through EP3 to regulate body temperature ([@B81]). Furthermore, the presence of a group of Ucn 3 cells in the MnPO ([@B70]) suggests that Ucn 3 might be involved in MnPO mediates pyrogenic effects.

REGULATION OF Ucn 3 EXPRESSION IN THE BRAIN
-------------------------------------------

The expression of Ucn 3 in the brain has been determined in a number of stress paradigms and metabolic challenges. It was found that restraint stress rapidly elevates Ucn 3 gene expression in the MeA and that the elevated Ucn 3 mRNA levels return to basal levels 4 h after the stress ([@B49]). Restraint stress also increases Ucn 3 mRNA levels in the rPFA but with a slower time course compared to that of the MeA ([@B129]; [@B49]). Adrenalectomy greatly elevates Ucn 3 expression in the rPFA, while corticosterone replacement returns the expression to a basal level ([@B49]). This result indicates that corticosterone may be involved in stress-mediated Ucn 3 gene expression in the rPFA. Hemorrhage decreases Ucn 3 expression in the MeA after 30 min, and 48 h of food deprivation also decreases Ucn 3 expression in the MeA ([@B49]).

The expression of Ucn 3 has also been examined in genetically obese rodent models. Food deprivation increases Ucn 3 mRNA expression in the dorsal part of the medial amygdala (MeD) in obese Fa/Fa Zuker rats and has no effect on Ucn 3 expression in the rPFH ([@B95]). In contrast, lean Fa/? rats show increased Ucn 3 expression in the rPFH but not the MeD after food deprivation ([@B95]). Ucn 3 mRNA expression returns to normal after 24 h of refeeding ([@B95]). In ob/ob obese mice, Ucn 3 expression is significantly reduced in the MeA (**Figure [1](#F1){ref-type="fig"}**; [@B69]), and leptin treatment reverses Ucn 3 expression in this area. Interestingly, pair-feeding in ob/ob mice failed to modulate Ucn 3 expression in the MeA. These results indicate that Ucn 3 expression in the MeA is regulated by leptin. Taken together, these studies further support the notion that endogenous Ucn 3 in the brain is sensitive to metabolic signals and energy status and potentially plays an important role in regulating energy homeostasis.

![**Representative darkfield photomicrographs showing Ucn 3 mRNA expression (white clusters) in a wildtype mouse (A), an ob/ob obese mouse (B), and an ob/ob mouse treated with leptin (0.1 mg/kg/day for 2 days) (C)**. **(D)** Summary of Ucn 3 mRNA levels in the MeA of WT and Ob/ob obese mice treated with vehicle or leptin. The Ucn 3 mRNA levels in an additional group of Ob/ob mice that was paired-fed were also determined. Different letters represent statistical significance: *p* \< 0.05. MeApd, medial nucleus of amygdala, posterodorsal part; opt, optic tract. Scale bar = 20 μm.](fendo-03-00180-g001){#F1}

THE VENTROMEDIAL HYPOTHALAMUS
=============================

The anatomical distribution of CRF~2~ in the brain has provided important insight into possible areas that mediate the effects of CRF~2~ in energy balance. The VMH has received significant attention due to its abundant expression of CRF~2~ and well-known role in regulating energy homeostasis, feeding, and blood glucose levels.

The VMH is parceled on cytoarchitectonic grounds into three major divisions: dorsomedial (VMHdm), central, and the ventrolateral (VMHvl) parts ([@B41]). The VMH volume is larger in males compared with females, and this difference is largely accounted for by the VMHvl, which in females is significantly smaller than that in males ([@B29]). Further, VMHvl in female rats express higher levels of estrogen receptors than that in males, and has been shown to play a critical role in regulating lordosis behavior in females ([@B35]) and aggressiveness in males ([@B71]).

The VMH has long been considered a critical brain area in the regulation of energy homeostasis. Lesion of the VMH results in hyperphagia, hyperinsulinemia, reduction of SNS activity, increase of fat mass, and reduction of energy expenditure that ultimately leads to storage of excess of energy and obesity ([@B7]; [@B47]; [@B25]; [@B84]; [@B104]; [@B101]; [@B54]). Conversely, stimulation of the VMH results in predominately opposite phenotypes including induction of satiety, increase in SNS activity, lipolysis, and thermogenesis ([@B54]). In recent years, the importance of the VMH in energy homeostasis has been further ascertained with the aid of improved molecular tools and mouse genetics ([@B114]; [@B54]; [@B18]). For example, mice with VMH-specific deletion of a number of genes including the leptin receptor ([@B27]; [@B8]), estrogen receptor α ([@B82], [@B83]), and vesicular glutamate transporter-2 (VGLUT2; [@B123]) result in a number of abnormalities such as increased feeding, reduced energy expenditure, impaired glucose homeostatic regulation, and obesity. Moreover, mice bearing a deletion of steroidogenic factor 1 (SF1), a transcription factor involved in steroidogenesis that is highly enriched in the VMH, show similar phenotypes in energy homeostasis and are obese ([@B74]; [@B103]; [@B108]).

EXPRESSION OF CRF~2~ IN THE VMH
-------------------------------

The VMH is one of the brain areas with prominent CRF~2~ expression ([@B17]; [@B127]). The expression is concentrated in the dorsomedial part of the nucleus with decreasing density toward the ventrolateral division of the VMH. The expression of CRF~2~ in the VMH has been shown to be sensitive to energy status and stress. For example, leptin injection increases and fasting decreases CRF~2~ expression in the VMH and ob/ob mice or Fa/Fa Zucker rats have lower CRF~2~ in the VMH compared to WT controls ([@B99]; [@B76], [@B75]; [@B85]). Furthermore, restraint stress and glucocorticoids increase CRF~2~ levels in the VMH ([@B76], [@B75]). Thus, these data support the notion that CRF~2~ in the VMH is important in regulating energy balance.

Currently, detailed neurochemical phenotypes of CRF~2~-positive cells within the VMH remain unclear. Several proteins have been found to be expressed in the VMH including SF1, pituitary adenylate cyclase-activating polypeptide, the leptin receptor, and VGLUT2 ([@B33]; [@B31]; [@B135]; [@B107]; [@B63]). It has been shown that CRF~2~ extensively colocalizes with VGLUT2 in the VMH ([@B22]). VGLUT2 mediates glutamate uptake into synaptic vesicles of excitatory neurons ([@B36]; [@B44]; [@B120]) and has been used extensively as a marker for excitatory glutamatergic neurons. The colocalization of CRF~2~ and VGLUT2 suggests that CRF~2~ is expressed predominately in excitatory neurons in the VMH. As mentioned above, SF1 is a nuclear receptor that regulates the transcription of key genes involved in sexual development and reproduction ([@B89]). In adults, SF1 expression is specifically confined to the VMH ([@B89]). In SF1 null mice, CRF~2~ mRNA expression is nearly undetectable in the VMH ([@B74]; [@B103]; [@B108]), suggesting CRF~2~ is expressed in SF1 cells in the VMH. Consistent with this notion, it was found that more than 90% of CRF~2~ neurons in the dorsomedial part of the nucleus are also SF1-positive (**Figure [2](#F2){ref-type="fig"}**) with less colocalization of these two materials in the VMHvl ([@B28]).

![**(A)** Darkfield photomicrograph showing CRFR2 mRNA signal revealed by *in situ* hybridization in the basal hypothalamic area of a transgenic mouse expressing Cre recombinase (Cre) and enhanced yellow fluorescent protein (EYFP) in SF1-positive cells. Note that CRFR2 mRNA hybridization signal (white clusters) was abundant in the dorsomedial part of the VMH (VMHdm). **(B)** Bright field photomicrograph of the same area in **(A)** showing SF1-positive cells, revealed by immunostaining with anti-green fluorescent protein antibody (darkbrown precipitates) in the VMH. **(C)** High magnification of boxed area in **(A)** showing colocalization of CRFR2 (black dot clusters) and SF1 (brown precipitates) in the VMH. ARH, arcuate nucleus of hypothalamus; V3, third ventricle; VMHc, central part of the VMH; VMHdm, dorsomedial part of the VMH; VMHvl, ventrolateral part of the VMH. Scale bar = 50 μm **(B)**, 20 μm **(C)**.](fendo-03-00180-g002){#F2}

CRF LIGANDS INPUT INTO THE VMH
------------------------------

The anatomical distribution of a number of the CRF family peptides has been determined, and it was found that CRF and Ucn 1-expressing neurons provide minor innervation to the VMH ([@B116]; [@B57]; [@B9]). Interestingly, low levels of Ucn 1-immunoreactivity have been detected in cells in the VMH ([@B57]), suggesting Ucn 1 may be a local factor in the nucleus. Although Ucn 2 fiber distribution has not been determined, Ucn 2-positive cells have been found in a number of brain areas including the magnocellular part of the PVH, locus ceruleus, and facial motor nucleus ([@B98]), and none of these areas provide extensive projection into the VMH ([@B79]; [@B73]; [@B6]; [@B55]; [@B134]; [@B32]; [@B21]). Compared to other CRF innervations, Ucn 3 neuronal fibers abundantly innervate the VMH ([@B70]). Similar to the expression of CRF~2~ in the VMH, Ucn 3-positive axonal fibers and terminals concentrate in the dorsomedial part of the VMH with reduced density toward the ventrolateral part of the nucleus ([@B70]). As stated above, Ucn 3 neurons in the PVHap provide the major Ucn 3 afferent input into the VMH and Ucn 3 cells in the pBNST and the MeA comparatively provide moderate input into the nucleus ([@B21]). Interestingly, Ucn 3 cells in the rPFH, immediately caudal and adjacent to the PVHap, provide minimal Ucn 3 afferent input into the VMH and instead send strong innervation into the LS.

Neural inputs into the PVHap and MeA have been studied ([@B106]; [@B115]; [@B124]; [@B77]; [@B15]; [@B86]; [@B97]; [@B126]). In general, the two brain areas receive similar afferent input from a number of brain regions including the septal nuclei and amygdala. However, a few subtle but significant exceptions should be noted. The PVHap receives prominent inputs from the hypothalamus, cortex, and brainstem, whereas the MeA receives strong inputs from the bed nucleus of the accessory olfactory tract and nucleus of stria medullaris. These findings suggest Ucn 3 cells in the PVHap receive inputs that transmit visceral and autonomic information while the Ucn 3 cell group in the MeA receives afferents that relay olfactory information. Thus, it is conceivable that central Ucn 3 may serve as a common peptide neurotransmitter in the various neural pathways that convey information from assorted neural signals into the VMH to coordinate the regulation of energy homeostasis.

FUNCTION OF CRF~2~ IN THE VMH
-----------------------------

When the function of CRF~2~ in the VMH was first assessed by injecting Ucn 1 into the VMH, it was found that the peptide potently suppresses food intake ([@B88]). However, because CRF~1~ has been suggested to be expressed in the VMH ([@B23]) and Ucn 1 has equally high affinity for both CRF~1~ and CRF~2~ ([@B128]), it remains possible that CRF~1~ may also contribute to the anorectic effect of Ucn 1 in the VMH. More recently, when the CRF~2~-selective ligand Ucn 3 was identified ([@B66]), the function of CRF~2~ in the VMH was re-examined by site-specific injection of Ucn 3 into the VMH ([@B34]; [@B22]). Consistent with the Ucn 1 injection study, stimulation of CRF~2~ by Ucn 3 in the VMH significantly suppresses feeding. Moreover, stimulation of CRF~2~ in other regions including the PVH, amygdala, and the lateral hypothalamus fails to modulate feeding ([@B88]; [@B34]; [@B22]), reinforcing the notion that VMH CRF~2~ plays a critical role in mediating the effect of CRF peptides in suppressing food intake.

In addition to appetite suppression, activation of CRF~2~ in the VMH results in rapid elevation of blood glucose levels ([@B22]). This is consistent with the function of VMH neurons in glucose homeostasis, as VMH neurons have been suggested to play an important role in regulating glucose levels via glucose sensing, and modulating glucose production in peripheral tissues ([@B50]; [@B65]). On the other hand, it has been shown that stimulation of CRF~2~ in the VMH suppresses insulin-induced release of glucagon and epinephrine ([@B80]), indicating that VMH CRF~2~ exerts a negative control over the counterregulatory response (CRR). Taken together, it is possible that the functional role of CRF~2~ in the VMH in glucose homeostasis is context dependent. When blood glucose is low as a result of hyperinsulinemia, CRF~2~ in the VMH negatively regulates the CRR response. On the other hand, under normoglycemia, CRF~2~ induces acute hyperglycemia to facilitate fuel mobilization perhaps in response to stress. We have also found that CRF~2~-positive neurons in the VMH are sensitive to glucose, as high glucose inhibits and low glucose stimulates the neuronal activity ([@B28]).

Type 2 CRF receptor has been shown to modulate the HPA axis. For example, CRF~2~ KO mice display altered HPA hormonal secretion, and central Ucn 3 injection facilitates stress-induced ACTH secretion ([@B49]). On the other hand, activation of CRF~2~ in the VMH fails to modulate HPA hormone secretion ([@B22]), indicating that the receptor in the VMH is not essential for central Ucn 3-induced HPA activation. Thus, CRF~2~-positive brain loci that are important for modulation of the HPA axis remain to be determined.

PHYSIOLOGICAL ROLE OF CRF~2~ IN THE VMH
---------------------------------------

To probe the physiological role of endogenous CRF~2~ in the VMH, VMH-specific CRF~2~ knockdown mice were generated by injection of a lentiviral vector expressing CRF~2~ small hairpin RNA (shRNA; [@B18]). Mice injected with CRF~2~ shRNA displayed significantly reduced CRF~2~ mRNA levels and gain more weight, mostly in white fat, than control mice. Furthermore, similar to Ucn 3 null mice, mice with reduced CRFR2 in the VMH exhibited elevated basal food intake and ate more than the control mice after overnight fasting. This result indicates that CRF~2~ in the VMH serves as a brake to facilitate the cessation of feeding. This study suggests that CRF~2~ in the VMH plays a critical role in mediating the effect of central Ucn 3 in energy balance.

In addition to elevated feeding, mice with decreased expression of CRF~2~ in the VMH display reduced lipolysis and increased adiposity in white fat ([@B18]). This is likely due to reduced SNS activity, as the VMH has been shown to regulate lipolysis via sympathetic outflow ([@B60]; [@B119]; [@B101]). Interestingly, CRF~2~ knockdown in the VMH has no major impact in heat production or uncoupling protein 1 expression in BAT, suggesting that CRF~2~ in the VMH does not significantly modulate thermogenesis in BAT. This result appears to disagree with earlier reports that VMH is involved in regulating thermogenesis in BAT ([@B91]; [@B53]). Anatomical studies have demonstrated a compartment-specific organization of innervation of different peripheral organs, as abdominal fat and subcutaneous fat are innervated by different neural pathways ([@B58], [@B59]). It is possible that CRF~2~-positive neurons are a subpopulation of cells in the VMH that regulate SNS outflow to white fat without significant functional impact on BAT. Heterogeneity of VMH neurons has been reported as overlapping but distinct subpopulation of neurons in the VMHvl that are critical in regulating fighting and mating ([@B71]).

Consistent with the function of CRF~2~ in regulating blood glucose levels, mice with reduced CRF~2~ expression in the VMH show improved glucose homeostasis compared to control mice ([@B18]). Moreover, mice with CRF~2~ knocked down in the VMH exhibit an exaggerated rebound in blood glucose levels compared to control mice after the initial hypoglycemic response to insulin challenge. This result agrees with the study by [@B80], who found that injection of Ucn 3 into the VMH suppresses the hypoglycemia-induced CRR response. Taken together, these studies strongly argue that CRF~2~ is a critical molecular mediator in VMH regulation of glucose homeostasis.

NEUROCIRCUITS UNDERLYING THE EFFECT OF VMH
------------------------------------------

To understand how VMH CRF~2~ neurons regulate output functions and to describe an anatomical link between these neurons and the SNS, it is necessary to determine their axonal projections to identify downstream targets in the brain. A number of anterograde tracing studies utilizing different tracers have been performed to evaluate the projections of VMH neurons. Generally, it was found that VMH neurons project extensively to neighboring hypothalamic nuclei including the anterior and paraventricular nucleus, BNST, and periaqueductal gray (PAG; [@B105]; [@B13]). These anatomical studies raise an interesting dilemma. Although it is clear that VMH activity modulates SNS activity, these studies failed to observe direct VMH efferents within well-known autonomic centers in the brainstem. Thus, it was concluded that the VMH likely modulates SNS activity indirectly by first projecting to a relay center such as the PAG.

Recently, using a conditional viral tracing approach, we have found that VMH neurons project to a number of important brainstem autonomic centers including the parabrachial nucleus, C1 catecholaminergic cell group in the rostral ventrolateral medulla, and the nucleus of solitary tract ([@B72]). Moreover, we have used the same approach to find that CRF~2~-positive cells in the VMH show similar axonal projections to these brainstem areas (**Figure [3](#F3){ref-type="fig"}**; [@B72]). These studies demonstrate that VMH neurons, including cells that express CRF~2~, can potentially modulate SNS activity by direct projections to brainstem autonomic centers.

![**(A)** Darkfield photomicrograph showing the injection site (green circle) of an adenoviral vector encoding Cre-regulated expression of farnesylated green fluorescent protein (GFP~f~) delivered into the VMH of a CRFR2-Cre mouse. The expression of GFP~f~ is normally silenced due to a Cre-regulated transcription block sequence inserted upstream of GFP~f~ reporter cassette. In the presence of Cre, the transcription block sequence is removed to allow GFP~f~ to be expressed in Cre-positive cells. **(B)** Darkfield photomicrograph depicting the distribution of VMH CRFR2-positive fibers (golden staining) within the rostral ventrolateral medulla (RVLM). ARH, arcuate nucleus of hypothalamus; MARN, magnocellular reticular nucleus; ME, median eminence; Py, pyramidal tract; Tu, tuberal nucleus; V3, third ventricle; VII, facial nucleus; VMHdn, dorsomedial part of the ventromedial nucleus of hypothalamus. Scale bar = 50 μm.](fendo-03-00180-g003){#F3}

CONCLUSION
==========

The function of CRF peptides and their receptors in coordinating hormonal, neuronal, and behavioral responses to stress is well recognized. Pharmacological studies have determined that the CRF~2~ receptors are involved in the regulation of energy homeostasis. Recent studies using various genetic mouse models and molecular tools have further ascertained the critical role of CRF~2~ and its selective ligands, including Ucn 3, in feeding, blood glucose regulation, SNS output, and peripheral metabolism. Moreover, CRF~2~ in the VMH mediates most, if not all, of the effects of central Ucn 3 on energy homeostasis.

It is clear that conflicting results have been observed between whole body and region- or tissue-specific KO or overexpression mouse models. Furthermore, several studies have demonstrated that anatomical or even functional heterogeneity exists within a seemingly single Ucn 3 cell population in the hypothalamus. Thus, a more detailed understanding of the physiological function of CRF~2~ and its selective ligands in the brain will be aided by brain region-specific transgenic animal models permitting manipulation of ligand or receptor expression. Study of such models will provide insight into the specific roles of CRF~2~ in modulating metabolic functions.

Regulation of energy balance under diverse challenges including stress, starvation, or high-fat diet requires numerous adaptive mechanisms in both central and peripheral tissues. It is now clear that central CRF~2~ and Ucn 3 are involved in this regulation, as the expression of the receptor and ligands are closely regulated under these challenges. It is thus conceivable that dysregulated CRF~2~ or ligand function potentially cause or exacerbate metabolic perturbations. This hypothesis can be easily tested with the above mentioned rodent models to determine the functional role of the CRF~2~ system in metabolic diseases. Moreover, a better understanding of the molecular mechanisms by which various stressors or metabolic signals regulate the expression and/or function of CRF~2~ and its ligand will provide significant insight into the potential role of the CRF family and its receptors in the pathophysiology of metabolic disorders including obesity and diabetes.
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